GlassScriptPhysician profile
Ashley N Daniel
NPI 1306417548
$5,456.64
in general payments reported to CMS, 2019-2025
26 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $129 · 2023: $754 · 2024: $2,179 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $954.25 | 2023-2025 | Lokelma, Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $612.81 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $597.23 | 2023-2025 | Verquvo, Winrevair, Capvaxive |
| Novo Nordisk INC | $572.15 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.44 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $272.96 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $251.14 | 2023-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $246.89 | 2023-2025 | Amvuttra |
| Abiomed | $219.98 | 2023-2025 | Impella |
| Cvrx, INC. | $181.17 | 2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $176.52 | 2022-2024 | Xarelto |
| Pfizer INC. | $160.77 | 2022-2025 | |
| Abbott Laboratories | $152.72 | 2025 | Mitraclip |
| Philips North America LLC | $152.59 | 2023-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Chiesi USA, INC. | $121.65 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $108.82 | 2024 | Aurora Ev-Icd Mri Surescan |
| Esperion Therapeutics, INC. | $84.95 | 2024-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.71 | 2024-2025 | Lifevest |
| Inspire Medical Systems, INC. | $34.45 | 2023-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $33.67 | 2025 | |
| Bridgebio Pharma, INC. | $33.05 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $25.22 | 2025 | Evkeeza |
| Daiichi Sankyo INC. | $23.74 | 2025 | Injectafer |
| Daxor Corporation | $22.65 | 2024 | Bva-100 |
| Lexicon Pharmaceuticals, INC. | $18.55 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.